A relatively new therapy used to treat pulmonary arterial hypertension in those with mild to moderate disease was found to be effective at preventing death in those with more advanced disease. Results ...

A study of HB-1614 suggests it may improve exercise capacity in adults with pulmonary hypertension associated with ...

Shares of Insmed Incorporated (INSM) soared 25% in Tuesday’s pre-market after the company announced positive results from a ...

A novel screening approach developed by physicians at the Lewis Katz School of Medicine at Temple University shows ...

Pulmonary hypertension (PH) is a rare, progressive, debilitating condition characterised by elevated pulmonary artery ...

Sotatercept significantly reduced the risk of all-cause mortality, lung transplantation, or ≥24-hour hospitalization for ...

Keros Therapeutics Inc (NASDAQ:KROS) released topline data from the TROPOS Phase 2 trial of cibotercept (KER-012) in ...

In this randomized controlled trial of patients with pulmonary arterial hypertension (PAH) and high risk of mortality, ...

TPIP trial exceeds expectations; Phase 3 studies to begin by early 2026 Shares in Insmed Incorporated (NASDAQ:INSM) closed 28 ...

The pulmonary arterial hypertension treatment market has witnessed a significant transformation in recent years, driven by advancements in medical research and increasing awareness about rare ...